<DOC>
	<DOCNO>NCT01271972</DOCNO>
	<brief_summary>This open-label , multicenter , ascend , multiple dose study nesvacumab ( REGN910/ SAR307746 ) administer IV every 2 week .</brief_summary>
	<brief_title>Study Nesvacumab ( REGN910/ SAR307746 )</brief_title>
	<detailed_description />
	<criteria>1 . Confirmed diagnosis advance solid malignancy . 2 . ECOG performance status 0 1 3 . Adequate hepatic , renal bone marrow function 4 . At least 3 week since last dose chemotherapy , hormonal therapy radiotherapy 5 . At least 6 week since last dose bevacizumab 6 . At least 4 week since last surgery 7 . At least 4 week since last dose investigational treatment 1 . Patients brain metastasis , spinal cord compression , carcinomatous meningitis , evidence central nervous system involvement 2 . Patients serious non heal wound acute ulcer 3 . Either systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &gt; 95 mm Hg 4 . Patients medical history myocardial infarction , unstable angina pectoris , coronary/ peripheral artery bypass graft , congestive heart failure ventricular arrhythmia 5 . Patients deep vein thrombosis pulmonary embolism within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>